Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)

NCT03979131 is registered in ClinicalTrials.gov with Vall d'Hebron Institute of Oncology as lead sponsor.

NCT NCT03979131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Avelumab Plus Chemotherapy in the Peri-operative Treatment for Patients With Resectable Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC)
Lead sponsor
Vall d'Hebron Institute of Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 22, 2019
Completion date
June 15, 2026
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal junction adenocarcinoma, stomach neoplasms